JP2019504882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504882A5 JP2019504882A5 JP2018557209A JP2018557209A JP2019504882A5 JP 2019504882 A5 JP2019504882 A5 JP 2019504882A5 JP 2018557209 A JP2018557209 A JP 2018557209A JP 2018557209 A JP2018557209 A JP 2018557209A JP 2019504882 A5 JP2019504882 A5 JP 2019504882A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- histidine
- concentration
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152767 | 2016-01-26 | ||
| EP16152767.6 | 2016-01-26 | ||
| EP16199497.5 | 2016-11-18 | ||
| EP16199497 | 2016-11-18 | ||
| PCT/EP2017/051662 WO2017129685A1 (en) | 2016-01-26 | 2017-01-26 | Liquid formulation of a vegf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504882A JP2019504882A (ja) | 2019-02-21 |
| JP2019504882A5 true JP2019504882A5 (cg-RX-API-DMAC10.html) | 2019-12-12 |
| JP6953433B2 JP6953433B2 (ja) | 2021-10-27 |
Family
ID=57882094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557209A Expired - Fee Related JP6953433B2 (ja) | 2016-01-26 | 2017-01-26 | Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10576128B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3407868A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6953433B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017213103B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3011638C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017129685A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
| WO2018063963A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| CN109937034B (zh) * | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| CN114617999B (zh) | 2017-03-27 | 2024-12-27 | 里珍纳龙药品有限公司 | 灭菌方法 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| US20200255496A1 (en) | 2017-09-18 | 2020-08-13 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| WO2019099921A2 (en) * | 2017-11-17 | 2019-05-23 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| MY202872A (en) * | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| CN111699004A (zh) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| WO2020047067A1 (en) * | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| WO2020055123A1 (ko) * | 2018-09-10 | 2020-03-19 | 삼성바이오에피스 주식회사 | 단백질을 포함하는 액상 조성물 |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| JP7713950B2 (ja) * | 2020-03-04 | 2025-07-28 | 上海復宏漢霖生物技術股▲フン▼有限公司 | ベバシズマブを含む薬物製剤 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| EP4190310A4 (en) * | 2020-07-31 | 2024-01-17 | Celltrion, Inc. | Stable pharmaceutical preparation |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| US11723955B1 (en) * | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025217334A1 (en) * | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124449A (en) | 1990-06-11 | 2000-09-26 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US5731144A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands |
| US5731424A (en) | 1990-06-11 | 1998-03-24 | Nexstar Pharmaceuticals, Inc. | High affinity TGFβ nucleic acid ligands and inhibitors |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| ES2276405T3 (es) | 1995-06-02 | 2007-06-16 | Gilead Sciences, Inc. | Ligandos de oligonucleotidos de alta afinidad a pdgf. |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| CA2654510C (en) * | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| WO2007148334A1 (en) * | 2006-06-20 | 2007-12-27 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic peptides and hydrogel matrices thereof for bone repair |
| JP2010531340A (ja) | 2007-07-10 | 2010-09-24 | エフ．ホフマン−ラ ロシュ アーゲー | 新規処方物 |
| KR20180005753A (ko) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| JP2015519373A (ja) * | 2012-06-01 | 2015-07-09 | オプソテック コーポレイションＯｐｈｔｈｏｔｅｃｈ Ｃｏｒｐｏｒａｔｉｏｎ | 抗ｐｄｇｆアプタマーおよびｖｅｇｆ拮抗薬を含む組成物 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014033184A1 (en) | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| JP2016522249A (ja) * | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用 |
| ES2875878T3 (es) * | 2013-11-18 | 2021-11-11 | Formycon Ag | Composición farmacéutica de un anticuerpo anti-VEGF |
| WO2015173260A1 (en) | 2014-05-12 | 2015-11-19 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| US20180326126A1 (en) | 2015-11-18 | 2018-11-15 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
| EP3407868A1 (en) | 2016-01-26 | 2018-12-05 | Formycon AG | Liquid formulation of a vegf antagonist |
-
2017
- 2017-01-26 EP EP17701350.5A patent/EP3407868A1/en active Pending
- 2017-01-26 WO PCT/EP2017/051662 patent/WO2017129685A1/en not_active Ceased
- 2017-01-26 AU AU2017213103A patent/AU2017213103B2/en active Active
- 2017-01-26 CA CA3011638A patent/CA3011638C/en active Active
- 2017-01-26 JP JP2018557209A patent/JP6953433B2/ja not_active Expired - Fee Related
- 2017-01-26 US US16/072,638 patent/US10576128B2/en active Active
-
2020
- 2020-01-14 US US16/742,585 patent/US20200237862A1/en not_active Abandoned
-
2023
- 2023-02-23 US US18/173,549 patent/US12551529B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2722643C2 (ru) | Способ лечения болезней глаз | |
| Theodossiadis et al. | Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration | |
| KR101808234B1 (ko) | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 | |
| JP2024042697A (ja) | 眼疾患を治療するための方法 | |
| US12214049B2 (en) | Anti-angiogenic antibody-drug conjugates | |
| JP2016528202A5 (cg-RX-API-DMAC10.html) | ||
| JP2015528454A5 (cg-RX-API-DMAC10.html) | ||
| US10010513B2 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| JP2019510739A5 (cg-RX-API-DMAC10.html) | ||
| JP2014532072A5 (cg-RX-API-DMAC10.html) | ||
| JP2020532562A5 (cg-RX-API-DMAC10.html) | ||
| HRP20170130T1 (hr) | Načini liječenja dijabetesa antagonistima gena dll4 | |
| JP2015510882A5 (cg-RX-API-DMAC10.html) | ||
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| US20250197486A1 (en) | Methods for treating neovascular age-related macular degeneration | |
| KR20220062279A (ko) | 안질환의 치료 방법 | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| CA3235778A1 (en) | Methods of use and administration of encapsulated cells | |
| Saeed et al. | Reflux of drug during intra-vitreal anti-VEGF therapies | |
| RU2015133365A (ru) | Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно | |
| Lazić et al. | Age Related Macular Degeneration | |
| KR20260019535A (ko) | 보체 항체-약물 접합체 | |
| RU2771900C2 (ru) | Способ лечения болезней глаз | |
| RU2024102531A (ru) | Состав на основе раствора белка, содержащий антитело к vegf в высокой концентрации | |
| Kim | Lucentis® |